Hims & Hers Health, Inc. (NYSE: HIMS) reported Q4 EPS of $0.11, $0.06 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $481.1 million versus the consensus estimate of $469.33 million.

GUIDANCE:

Hims & Hers Health, Inc. sees FY2025 revenue of $2.3-2.4 billion, versus the consensus of $2.09 billion.

• Adjusted EBITDA of $270 million to $320 million, reflecting an Adjusted EBITDA margin of 12% to 13%.

Hims & Hers Health, Inc. sees Q1 2025 revenue of $520-540 million, versus the consensus of $482.5 million.

• Adjusted EBITDA of $55 million to $65 million, reflecting an Adjusted EBITDA margin of 11% to 12%.

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.

Earnings Guidance Hot Earnings Hot Guidance

Hims and Hers (HIMS) PT Raised to $61 at NeedhamFebruary 25, 2025 6:07 AM Leerink Partners Reiterates Market Perform Rating on Hims and Hers (HIMS)February 25, 2025 5:36 AM Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)February 25, 2025 5:35 AM Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)February 25, 2025 5:34 AM BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $21February 25, 2025 5:17 AM BTIG Reiterates Buy Rating on Hims and Hers (HIMS)February 25, 2025 5:11 AM Hims and Hers (HIMS) PT Raised to $27 at Citi, Maintains Sell 'as we await a better entry point and more details on growth outside GLP-1s'February 25, 2025 4:58 AM